The biomarker landscape in mycosis fungoides and Sézary syndrome.
Exp Dermatol
; 26(8): 668-676, 2017 08.
Article
en En
| MEDLINE
| ID: mdl-27897325
ABSTRACT
The practice of pre-emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome, highlighting the most promising molecules in different compartments. Further, we emphasize the need for continued multicentre efforts to validate available and new biomarkers and to develop prospective combinatorial panels of already discovered molecules.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Biomarcadores
/
Micosis Fungoide
/
Síndrome de Sézary
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Exp Dermatol
Asunto de la revista:
DERMATOLOGIA
Año:
2017
Tipo del documento:
Article
País de afiliación:
Estados Unidos